|
Board of Directors and Company Secretary Dr Paul Harper, ChairmanDr Paul Harper has over 30 years' experience in the life sciences industry covering both drug development and medical devices. Paul has served as Chief Executive of Cambridge Antibody Technology Limited, and Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever PLC, and as Director of Research and Development for Johnson & Johnson Limited. Formerly head of Antimicrobial Chemotherapy for Glaxo PLC, Paul has a PhD in Molecular Virology and is the author of over 50 publications. Dr Christophe Chassagnole, Chief Operating Officer Dr Christophe Chassagnole has been involved in Systems Biology projects during the 10 last years, with experience in both academic and industrial environments. His Doctorate was achieved at the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before Joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years. He joined Physiomics in May 2004 as project leader to develop the model portfolio of the company. He was appointed Chief Operating Officer of Physiomics in May 2007. Mr Roger Jones, Company Secretary Mr. Jones has for 30 years been a Fellow of the Association of Chartered Certified Accountants and has held a number of senior financial positions and key roles in biotechnology and pharmaceutical companies including Cambridge Antibody Technology, Onyvax, Archimedes Pharma, Angel Biotechnology and Provensis.
This part of the website has been designed to comply with the requirements of Rule 26 of the AIM Rules for Companies - 'Company information disclosure' Document Last Updated Tuesday, 28 July 2008
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||